Guo et al.
1
recently investigated the role of a key regulator of intracellular hypoxia inducible factor 1 (HIF-1) in the reduced angiogenesis associated with diabetes in abdominal aortic aneurysm (AAA). Using an elastase model and streptozotocin induced diabetes, they showed that decreased AAA formation observed in diabetic mice may be due to dysregulated HIF-1α mediated angiogenesis.- Guo J.
- Shoji T.
- Ge Y.
- Zheng X.
- Li Y.
- Zhao S.
- et al.
Treatment with the prolyl hydroxylase inhibitor JNJ promotes abdominal aortic aneurysm progression in diabetic mice.
Eur J Vasc Endovasc Surg. 2021; ([Epub ahead of print])https://doi.org/10.1016/j.ejvs.2021.10.030
1
The translational relevance remains to be investigated. Although diabetes may protect against AAA, the effect is only partial as diabetic patients still develop the disease. The mechanisms involved are multifactorial and are linked to diabetes itself, as well as antidiabetic drugs.- Guo J.
- Shoji T.
- Ge Y.
- Zheng X.
- Li Y.
- Zhao S.
- et al.
Treatment with the prolyl hydroxylase inhibitor JNJ promotes abdominal aortic aneurysm progression in diabetic mice.
Eur J Vasc Endovasc Surg. 2021; ([Epub ahead of print])https://doi.org/10.1016/j.ejvs.2021.10.030
2
,3
Streptozotocin is an experimental model of type 1 diabetes and may not be representative of human disease as type 2 diabetes accounts for 90% of diabetic patients.2
Finally, the investigators explored HIF-1α expression in aneurysmal aortic tissue of patients, but the small sample size (n = 2) does not allow robust conclusions to be drawn.1
This study brings perspectives to the use anti-angiogenesis therapy, but further studies are required before testing it in patients with AAAs.- Guo J.
- Shoji T.
- Ge Y.
- Zheng X.
- Li Y.
- Zhao S.
- et al.
Treatment with the prolyl hydroxylase inhibitor JNJ promotes abdominal aortic aneurysm progression in diabetic mice.
Eur J Vasc Endovasc Surg. 2021; ([Epub ahead of print])https://doi.org/10.1016/j.ejvs.2021.10.030
References
- Treatment with the prolyl hydroxylase inhibitor JNJ promotes abdominal aortic aneurysm progression in diabetic mice.Eur J Vasc Endovasc Surg. 2021; ([Epub ahead of print])https://doi.org/10.1016/j.ejvs.2021.10.030
- Diabetes and aortic aneurysm: current state of the art.Cardiovasc Res. 2018; 114: 1702-1713
- Editor's Choice – Association between metformin prescription and abdominal aortic aneurysm growth and clinical events: a systematic review and meta-analysis.Eur J Vasc Endovasc Surg. 2021; 62: 747-756
Article info
Publication history
Published online: March 10, 2022
Accepted:
December 24,
2021
Received:
December 7,
2021
Identification
Copyright
© 2022 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- Response to: “Decreased Angiogenesis in Diabetes: New Insights into the Mechanisms Involved in the Negative Association Between Diabetes and Abdominal Aortic Aneurysm”European Journal of Vascular and Endovascular SurgeryVol. 63Issue 4
- PreviewAs noted,1 multiple potential mechanisms suppress abdominal aortic aneurysms (AAAs) in patients with diabetes.2–4 While aetiologically distinct, both types one and two diabetes produce the chronic hyperglycaemia causal for nearly all related pathologies. Streptozotocin produced rapid and reproducible induction of hyperglycaemia without introducing confounding influences due to the deficient leptin receptor activity or obesity present in spontaneous and diet induced type 2 murine modelling systems, respectively.
- Full-Text
- Preview
Related Articles
Comments
Commenting Guidelines
To submit a comment for a journal article, please use the space above and note the following:
- We will review submitted comments as soon as possible, striving for within two business days.
- This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
- We require that commenters identify themselves with names and affiliations.
- Comments must be in compliance with our Terms & Conditions.
- Comments are not peer-reviewed.
